Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Files NDA for Prevnar 13 for Infant Use
July 30, 2012
- Kobayashi Kako Completes Construction of Anticancer Drug Manufacturing Facility
July 30, 2012
- Alfresa Launches Advanced Temperature-controlled Distribution Service
July 30, 2012
- Chugai’s 1st-Half Sales Excluding Tamiflu Down 0.3% in Japan as Mircera Slumps
July 30, 2012
- Chugai Had Tough Start in Final Year of Midterm Plan: Chairman Nagayama
July 30, 2012
- Takeda Initiates PIII Trial for Anticancer Agent Motesanib in Asia
July 27, 2012
- Serum Ca Levels Show No Increase in Coadministration of Forteo, Activated Vitamin D3: Eli Lilly Japan
July 27, 2012
- Keizai Doyukai Chairman Hasegawa Instructs Takeda to Create Countermeasures for Risk of Violence in Emerging Countries
July 27, 2012
- Tarceva Shows No Significant Difference in PIII Study, Indication for Hepatoma Difficult: Astellas
July 26, 2012
- Kyowa Hakko Bio’s Subsidiary Completes Drug Substance Production Facility Conforming to Japan, US, Europe GMPs
July 26, 2012
- Takeda Receives Positive Opinion from CHMP on Adcetris
July 26, 2012
- Taiho Licenses Anti-Allergy Drug from Faes Farma in Japan
July 26, 2012
- Sandoz Launches Generic Claritin
July 26, 2012
- MTPC Launches Low-dose Anxiolytic Depas on July 24
July 26, 2012
- MSD Changes Name of Aroglycem to Diazoxide to Prevent Medication Errors
July 25, 2012
- MSD to File NDA for Odanacatib in Japan in First Half of 2013
July 25, 2012
- New Research Lab for Plasma Fractionation Business to Be Set Up in Kobe
July 25, 2012
- Nippon Kayaku to Increase Production of Carboplatin Due to Sandoz’s Shipment Suspension
July 25, 2012
- Meiji Seika Pharma Discontinues Development of Schizophrenia Treatment AM-831
July 24, 2012
- AnGes MG to Conduct Domestic PI/II Trials of Collategene for Lymphedema in Fall
July 24, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…